SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 1, 2016
STELLAR BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|British Columbia, Canada||000-54598||N/A|
|(State or other jurisdiction||(Commission||(I.R.S. Employer|
|of incorporation)||File Number)||Identification No.)|
332 E. Scott Street
Port Hueneme, California 93041
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|o||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|o||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|o||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|o||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously announced in a Current Report on Form 8-K filed with the Securities and Exchange Commission on October 24, 2016, effective December 1, 2016, Dr. Gregory T. Baxter was appointed as the Executive Vice President of Corporate Development of Stellar Biotechnologies, Inc. (the “Company”). As a result of and simultaneously with his appointment to the Company’s management team, Dr. Baxter, an independent member of the Company’s Board of Directors (the “Board”) resigned from the Board on December 1, 2016, effective immediately.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Stellar Biotechnologies, Inc.|
|Date: December 7, 2016||By:||/s/ Kathi Niffenegger|
|Title:||Chief Financial Officer|